CClinicalTrials.gg
Sign In
CompletedNCT02027376EDALINEUpdated Apr 3, 2023Results posted

Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients

A Phase 1 interventional study of LDE225 and Docetaxel in Advanced Breast Cancer, sponsored by Spanish Breast Cancer Research Group. Completed at 5 sites in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-03.

Sponsored by Spanish Breast Cancer Research Group · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

This is a single-arm, open-label, phase Ib study. In this trial, patients with Triple Negative (TN) Advanced Breast Cancer (ABC) will be treated with increasing doses of LDE225 (sonidegib) and docetaxel to determine the Maximum Tolerated Dose (MTD), Dose Limiting Toxicity (DLT) and Recommended Phase II Dose (RP2D) of the combination.

Eligible patients with hormonal receptors negative and Human Epidermal Growth Factor Receptor 2 (HER2) negative ABC will be included and treated with docetaxel intravenously in every three weeks cycles. LDE225 will be administered orally at three dose levels 400, 600 and 800mg one a day (QD) (a -1 dose level is included just in case dose de-escalation is needed). Treatment will be repeated on day 1 of a 21-day cycle until radiographic or symptomatic progression, unacceptable toxicity or withdraws informed consent.

The investigators propose to develop a phase Ib trial with the combination of docetaxel with LDE225 in TN ABC patients to define the safety, tolerability and RP2D, as well as to have some information about the efficacy of the combination.

Read the detailed description

Primary Objective:

To determine the MTD and RP2D of LDE225 administered orally in combination with docetaxel in TN ABC patients.

Primary End-point:

To determine the incidence rate of DLT within the first two cycles of LDE225 in combination with docetaxel at each dose level.

Secondary Objectives:

  • To determine the safety and tolerability of LDE225 given in combination with docetaxel.
  • To characterize the effects of LDE225 in combination with docetaxel on corrected QT (QTc) intervals and their correlation with systemic drug exposure.
  • To evaluate the efficacy of the combination of docetaxel with LDE225 in TN ABC patients.
  • To evaluate the Pharmacokinetics (PK) of the combination of docetaxel with LDE225.

Secondary End-points:

  • Safety will be assessed by standard clinical and laboratory tests (hematology, serum chemistry). Adverse events grade will be defined by the NCI CTCAE v4.0.
  • Changes in QT/QTc from baseline ECG values and correlation with systemic drug exposure.
  • The efficacy endpoints are Time To Progression (TTP) and Objective Response Rate (ORR). TTP is measured from the initiation of treatment till disease progression and ORR is defined by RECIST 1.1 criteria as complete response rate + partial response rate.
  • The PK will determine whether LDE225 influences the pharmacology of docetaxel. Blood samples will be taken at the times defined in the protocol.

Exploratory Objectives:

  • To study potential predictive biomarkers of efficacy by evaluating activation of Hh signaling pathway and related pathways.
  • To analyze the pharmacodynamic (PD) treatment effects on the expression of Smo related biomarkers and Hg target genes in correlative samples.
  • To correlate biomarker, PD and PK findings with efficacy and toxicity data.

Exploratory End-points:

  • Hh gene expression signature associated to pathway activation (at least Shh, Smo, Ptch1, Ptch2, Gli1, Gli2), analyzed in tumor samples.
  • Changes in Smo related pathway biomarkers (at least Gli1) in skin and blood correlative samples.
  • Pharmacodynamic and biomarker analysis results will be correlated with PK findings, efficacy and toxicity data.

Demographics and Baseline Characteristics:

Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. 95% confidence intervals will be provided for estimates of interest wherever possible.

Safety Analyses:

Adverse events data and serious adverse events will be reported in frequency tables (overall and by intensity). The safety analysis will be performed in the population that has received at least one dose of the drugs.

Efficacy Analyses:

Response will be analyzed in patients with measurable disease that have received at least one dose of the drugs.

TTP will be evaluated in all patients that have received at least one dose of the drugs.

Study population:

Patient with hormonal receptors negative and HER2 negative ABC.

02

Conditions studied

  • Advanced Breast Cancer

Browse trials for

Keywords

  • Advanced Breast Cancer
  • LDE225
  • Triple Negative
  • Hormonal Receptor negative
  • Her2 negative
03

In context

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's enrollment of 12 is below the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Spanish Breast Cancer Research Group is the lead sponsor of 48 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. The patient is capable to understand and comply with the protocol and has signed the informed consent document.
  2. Females with histologically confirmed advanced breast cancer.
  3. TN breast cancer by local laboratory determination. Hormonal Receptor (HR) negative defined as \< 1% positive cells by Immunohistochemistry (IHC) for both Estrogen Receptor (ER) and Progesterone Receptor (PgR), and HER2 negative defined as in situ hybridization (ISH) negative or IHC 0 or 1+ in the absence of ISH (Note: patients with IHC 2+ must have an ISH determination in order to confirm the HER2 negativity.
  4. Measurable or non-measurable disease according to RECIST 1.1 criteria.
  5. Patient is at least 18 years of age.
  6. World Health Organization (WHO) Performance Status ≤ 1.
  7. Life expectancy ≥ 12 weeks.
  8. Common laboratory values within normal range (...)
  9. A negative serum pregnancy test ≤ 72 hours before starting study treatment for pre-menopausal women and for women \< 1 year from the last menstruation date.

Exclusion criteria

Exclusion Criteria:

  1. Have received more than 3 prior chemotherapy regimens for ABC.
  2. Patients with untreated brain metastases. However, a patient with Central Nervous System (CNS) metastases may participate in this trial if > 4 weeks from therapy completion (incl. radiation and/or surgery), is clinically stable with respect to the tumor at the time of study entry and is not receiving corticosteroid therapy.
  3. Patients with acute or chronic liver or renal disease or pancreatitis.
  4. Patients with a second primary malignancy that is clinically detectable at the time of consideration for study enrollment.
  5. Patients unable to swallow tablets.
  6. History of a positive HIV test (HIV testing is not mandatory).
  7. History of a positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result (Hepatitis B or C testing is not mandatory).
  8. Impairment of gastrointestinal (GI) function or GI disease (e.g. ulcerative disease, uncontrolled nausea, vomiting, grade ≥ 2 diarrhea, malabsorption syndrome or small bowel resection).
  9. Peripheral vascular disease requiring active therapy or having had surgery \< 12 months prior to starting study drug.

  10. Impaired cardiac function or clinically significant heart disease (...)

    • A past medical history of clinically significant ECG abnormalities or a family history of prolonged QT-interval syndrome
    • Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
  11. Patients who are receiving treatment with medications that are known to be strong inhibitors or inducers of CYP3A4/5 (listed in Protocol Attachment 3) or drugs metabolized by CYP2B6 or CYP2C9 (listed in Protocol Attachment 3) that cannot be discontinued prior to study entry and for the duration of the study. Medications that are strong CYP3A4/5 inhibitors should be discontinued for at least 2 days, and strong CYP3A4/5 inducers for at least 1 week prior to initiating LDE225 dosing.
  12. Patients who have received chemotherapy within a period of time that is \< the cycle length used for that treatment (e.g. \< 3 weeks for fluorouracil, doxorubicine, epirubicin) prior to starting study drug or who have not recovered from the side effects of such therapy.
  13. Patients who have received biologic therapy (e.g. antibodies) ≤ 4 weeks prior to starting study drug or who have not recovered from the side effects of such therapy.
  14. Patients who have been treated with a small molecule therapeutic ≤ 5 t1/2 or ≤ 4 weeks (whichever is shorter) prior to starting study drug or who have not recovered from the side effects of such therapy.
  15. Patients who have received any other investigational agents ≤ 5 t1/2 or ≤ 4 weeks (whichever is shorter) prior to starting study drug or who have not recovered from the side effects of such therapy.
  16. Patients who have received wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
  17. Patients who are currently receiving treatment with therapeutic doses of warfarin sodium (Coumadin) who cannot discontinue this treatment at least 5 days prior to starting study drug.

  18. Patients who are currently receiving immunosuppressive treatment and in whom the treatment cannot be discontinued prior to starting study drug, except in the case of patients with basal cell carcinoma (BCC). Immunosuppressive treatment should be discontinued for at least 1 week prior to initiating LDE225 dosing.

    ...

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    LDE225 (sonidegib) plus docetaxel

    Eligible patients will be included and treated with docetaxel intravenously (75mg/m2)in every three weeks cycles and LDE225 will be administered orally at three dose levels 400, 600 and 800mg QD. Treatment will be repeated on day 1 of a 21-day cycle until radiographic or symptomatic progression, unacceptable toxicity or withdraws informed consent.

    Drug: LDE225 · Drug: Docetaxel

Interventions

  • DrugLDE225

    Also known as: Sonidegib

  • DrugDocetaxel

    Also known as: Taxotere

06

What researchers measure

Primary outcomes

  1. Incidence Rate of DLT Within the First Two Cycles of LDE225 (Sonidegib) in Combination With Docetaxel

    DLT was defined as the occurrence of any of the following adverse events or abnormal laboratory values (graded according to the NCI-CTCAE version 4.0) assessed as possibly, probably or definitively related to study drugs, occurring within the first two cycles of treatment: Neutropenia grade 4 lasting more than one week, febrile neutropenia, thrombocytopenia grade 3 with bleeding more than grade 2, thrombocytopenia grade 4, Increased plasma creatinine phosphokinase (CK) grade 3-4, any non-hematologic grade 4 toxicity, or grade 3 toxicity except nausea and vomiting, Grade 2 GI toxicity (except nausea and vomiting) lasting more than 2 weeks, Inability to resume dosing for cycles 2 or 3 at the current dose level within 14 days, due to treatment-related toxicity. Dose reductions in cycles 1 and 2 will be considered a DLT

    Time frame: Up to cycle 2

  2. Maximum Tolerated Dose (MTD) of LDE225 (Sonidegib) in Combination With Docetaxel

    MTD was determined by testing increasing doses of LDE225 on dose escalation cohorts 1 to 6 patients. MTD reflects the highest dose tested in which a DLT is experienced by 0 out of 3 or 1 out of 6 patients among the dose levels.

    Time frame: Through study treatment, an average of 2 months

  3. Recommended Phase II Dose (RP2D) of LDE225 (Sonidegib) in Combination With Docetaxel

    The RP2D was decided by the investigators taken into consideration the information obtained in the study and based on the MTD. To define the RP2D, information about toxicity observed during the full treatment were taken into consideration (relative dose intensity and toxicity observed).

    Time frame: Through study treatment, an average of 2 months

Secondary outcomes

  1. The Number of Participants Who Experienced Adverse Events (AE)

    Safety was assessed by standard clinical and laboratory tests \[vital signs including blood pressure, pulse and body temperature, triplicate 12-lead ECGs at screening and on day 1 of cycle 3, blood tests including hematology (hemoglobin, platelets count, red blood cells (RBC), white blood cells (WBC) with differential count and serum chemistry (serum creatinine, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP), creatine phosphokinase (CPK))\]. Adverse events grade were defined by the NCI CTCAE v4.0.

    Time frame: Through study treatment, an average of 2 months

  2. Changes in QT/QTc From Baseline and Cycle 3 ECG Values.

    The QTc intervals have been characterized by comparing QTc at baseline (QTc interval measured in milliseconds (msec) by Fridericia's formula) and at cycle 3 pre-dose, 1 hour post-dose, 2 hours post-dose, 4 hours post-dose and 6 hours post-dose.

    Time frame: From baseline to cycle 3

  3. Time To Progression (TTP)

    Tumor assessments were performed until disease progression in order to evaluate the TTP. TTP is defined as the time from the date of the first dose to the first date of objectively determined progressive disease. For patients not known to have objectively-determined progressive disease, TTP will be censored at the date of the last objective progression-free assessment. For patients who receive subsequent systemic anticancer therapy (after discontinuation from the study treatment) prior to objective disease progression, TTP will be censored at the date of last objective progression-free assessment prior to the initiation of postdiscontinuation systemic anticancer therapy.

    Time frame: Through study treatment, an average of 2 months

  4. LDE225 (Sonidegib) Trough Concentration (Pharmacokinetics (PK))

    To evaluate the effect of LDE225 on the docetaxel PK, the main pharmacokinetic parameters of docetaxel were estimated on Day 1 of Cycles 1 and 2 of treatment, and compared between them. PK parameters were estimated by non-compartmental approach using Phoenix® WinNonlin® software (version 7.0). In the case of the effect of docetaxel on the LDE225 PK, since patients were always under both drugs at all the assessed PK profiles, the trough LDE225 concentrations obtained in our study were compared with those simulated from a previous developed PK model from LDE225 given as monotherapy. Therefore, a population PK model of LDE225 reported in the literature and developed in healthy subjects and patients with advanced solid tumors was implemented in NONMEN version 7.3 program and Monte-Carlo simulations of LDE225 concentrations after the same doses than those of our study, were performed.

    Time frame: Up to cycle 2

  5. Docetaxel Clearance on Cycle 1 and Cycle 2 (Pharmacokinetics (PK))

    PK sampling of docetaxel was performed on Day 1 of Cycle 1 and 2 of treatment and docetaxel concentrations. Blood samples were collected into ethylenediaminetetraacetic acid (EDTA) K3 tubes and after plasma separation by centrifugation were stored at -70 degrees Celsius until analysis.

    Time frame: Cycles 1 and 2

  6. Objective Response Rate (ORR)

    Tumor response was assessed using RECIST 1.1 criteria. The best response across all treatment was recorded. ORR is defined as the percentage of patients with a complete or partial response out of the patients who had measurable disease at baseline.

    Time frame: Through study treatment, an average of 2 months

07

Results

Posted Dec 4, 2018

Participant flow

12 patients were enrolled in this trial in the 5 Spanish centers receiving at least one cycle of the combination of oral LDE225 (sonidegib) with intravenous docetaxel. 5 patients were included at Dose Level (DL) 1, 4 patients at DL 2 and 3 patients at DL 3. Two patients at DL 1 and 1 patient at DL 2 were replaced due to early progressive disease.

Participant flow — Overall Study
MilestoneLDE225 (Sonidegib) 400mg in Combination With DocetaxelLDE225 (Sonidegib) 600mg in Combination With DocetaxelLDE225 (Sonidegib) 800mg in Combination With Docetaxel
Started543
Completed443
Not completed100
Withdrew: Death100

Outcome measures

PrimaryIncidence Rate of DLT Within the First Two Cycles of LDE225 (Sonidegib) in Combination With Docetaxel

DLT was defined as the occurrence of any of the following adverse events or abnormal laboratory values (graded according to the NCI-CTCAE version 4.0) assessed as possibly, probably or definitively related to study drugs, occurring within the first two cycles of treatment: Neutropenia grade 4 lasting more than one week, febrile neutropenia, thrombocytopenia grade 3 with bleeding more than grade 2, thrombocytopenia grade 4, Increased plasma creatinine phosphokinase (CK) grade 3-4, any non-hematologic grade 4 toxicity, or grade 3 toxicity except nausea and vomiting, Grade 2 GI toxicity (except nausea and vomiting) lasting more than 2 weeks, Inability to resume dosing for cycles 2 or 3 at the current dose level within 14 days, due to treatment-related toxicity. Dose reductions in cycles 1 and 2 will be considered a DLT

Time frame:
Up to cycle 2
Reported as:
Count of participants · Participants
Incidence Rate of DLT Within the First Two Cycles of LDE225 (Sonidegib) in Combination With Docetaxel
ParticipantsLDE225 (Sonidegib) 400mg in Combination With DocetaxelLDE225 (Sonidegib) 600mg in Combination With DocetaxelLDE225 (Sonidegib) 800mg in Combination With Docetaxel
Incidence Rate of DLT Within the First Two Cycles of LDE225 (Sonidegib) in Combination With Docetaxel000
PrimaryMaximum Tolerated Dose (MTD) of LDE225 (Sonidegib) in Combination With Docetaxel

MTD was determined by testing increasing doses of LDE225 on dose escalation cohorts 1 to 6 patients. MTD reflects the highest dose tested in which a DLT is experienced by 0 out of 3 or 1 out of 6 patients among the dose levels.

Time frame:
Through study treatment, an average of 2 months
Reported as:
Number · mg
Maximum Tolerated Dose (MTD) of LDE225 (Sonidegib) in Combination With Docetaxel
mgLDE225 (Sonidegib) in Combination With Docetaxel
Maximum Tolerated Dose (MTD) of LDE225 (Sonidegib) in Combination With Docetaxel800
PrimaryRecommended Phase II Dose (RP2D) of LDE225 (Sonidegib) in Combination With Docetaxel

The RP2D was decided by the investigators taken into consideration the information obtained in the study and based on the MTD. To define the RP2D, information about toxicity observed during the full treatment were taken into consideration (relative dose intensity and toxicity observed).

Time frame:
Through study treatment, an average of 2 months
Reported as:
Number · mg
Recommended Phase II Dose (RP2D) of LDE225 (Sonidegib) in Combination With Docetaxel
mgLDE225 (Sonidegib) in Combination With Docetaxel
Recommended Phase II Dose (RP2D) of LDE225 (Sonidegib) in Combination With Docetaxel800
SecondaryThe Number of Participants Who Experienced Adverse Events (AE)

Safety was assessed by standard clinical and laboratory tests \[vital signs including blood pressure, pulse and body temperature, triplicate 12-lead ECGs at screening and on day 1 of cycle 3, blood tests including hematology (hemoglobin, platelets count, red blood cells (RBC), white blood cells (WBC) with differential count and serum chemistry (serum creatinine, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP), creatine phosphokinase (CPK))\]. Adverse events grade were defined by the NCI CTCAE v4.0.

Time frame:
Through study treatment, an average of 2 months
Reported as:
Number · number of participants with AE
The Number of Participants Who Experienced Adverse Events (AE)
number of participants with AELDE225 (Sonidegib) 400mg in Combination With DocetaxelLDE225 (Sonidegib) 600mg in Combination With DocetaxelLDE225 (Sonidegib) 800mg in Combination With Docetaxel
The Number of Participants Who Experienced Adverse Events (AE)543
SecondaryChanges in QT/QTc From Baseline and Cycle 3 ECG Values.

The QTc intervals have been characterized by comparing QTc at baseline (QTc interval measured in milliseconds (msec) by Fridericia's formula) and at cycle 3 pre-dose, 1 hour post-dose, 2 hours post-dose, 4 hours post-dose and 6 hours post-dose.

Time frame:
From baseline to cycle 3
Reported as:
Mean · milliseconds
Changes in QT/QTc From Baseline and Cycle 3 ECG Values.
millisecondsLDE225 (Sonidegib) in Combination With Docetaxel
Cycle 3, Predose28.5 (-26 to 82.5)
Cycle 3, 1 hour4.5 (-15 to 23.8)
Cycle 3, 2 hours9.5 (-5.2 to 24.3)
Cycle 3, 4 hours2.8 (-23 to 29.1)
Cycle 3, 6 hours4.3 (-15 to 23.2)
SecondaryTime To Progression (TTP)

Tumor assessments were performed until disease progression in order to evaluate the TTP. TTP is defined as the time from the date of the first dose to the first date of objectively determined progressive disease. For patients not known to have objectively-determined progressive disease, TTP will be censored at the date of the last objective progression-free assessment. For patients who receive subsequent systemic anticancer therapy (after discontinuation from the study treatment) prior to objective disease progression, TTP will be censored at the date of last objective progression-free assessment prior to the initiation of postdiscontinuation systemic anticancer therapy.

Time frame:
Through study treatment, an average of 2 months
Reported as:
Median · days
Time To Progression (TTP)
daysLDE225 (Sonidegib) 400mg in Combination With DocetaxelLDE225 (Sonidegib) 600mg in Combination With DocetaxelLDE225 (Sonidegib) 800mg in Combination With Docetaxel
Time To Progression (TTP)42.0 (29 to 84)42.5 (20 to 64)188 (155 to NA)
SecondaryLDE225 (Sonidegib) Trough Concentration (Pharmacokinetics (PK))

To evaluate the effect of LDE225 on the docetaxel PK, the main pharmacokinetic parameters of docetaxel were estimated on Day 1 of Cycles 1 and 2 of treatment, and compared between them. PK parameters were estimated by non-compartmental approach using Phoenix® WinNonlin® software (version 7.0). In the case of the effect of docetaxel on the LDE225 PK, since patients were always under both drugs at all the assessed PK profiles, the trough LDE225 concentrations obtained in our study were compared with those simulated from a previous developed PK model from LDE225 given as monotherapy. Therefore, a population PK model of LDE225 reported in the literature and developed in healthy subjects and patients with advanced solid tumors was implemented in NONMEN version 7.3 program and Monte-Carlo simulations of LDE225 concentrations after the same doses than those of our study, were performed.

Time frame:
Up to cycle 2
Reported as:
Mean · mg/L
LDE225 (Sonidegib) Trough Concentration (Pharmacokinetics (PK))
mg/LLDE225 (Sonidegib) 400mg in Combination With DocetaxelLDE225 (Sonidegib) 600mg in Combination With DocetaxelLDE225 (Sonidegib) 800mg in Combination With Docetaxel
LDE225 (Sonidegib) Trough Concentration (Pharmacokinetics (PK))0.398 ± 0.3350.392 ± 0.0860.727 ± 0.539
SecondaryDocetaxel Clearance on Cycle 1 and Cycle 2 (Pharmacokinetics (PK))

PK sampling of docetaxel was performed on Day 1 of Cycle 1 and 2 of treatment and docetaxel concentrations. Blood samples were collected into ethylenediaminetetraacetic acid (EDTA) K3 tubes and after plasma separation by centrifugation were stored at -70 degrees Celsius until analysis.

Time frame:
Cycles 1 and 2
Reported as:
Mean · L/h
Docetaxel Clearance on Cycle 1 and Cycle 2 (Pharmacokinetics (PK))
L/hLDE225 (Sonidegib) in Combination With Docetaxel
Cycle 1 Day 148.8 ± 19.6
Cycle 2 Day 142.7 ± 27.8
SecondaryObjective Response Rate (ORR)

Tumor response was assessed using RECIST 1.1 criteria. The best response across all treatment was recorded. ORR is defined as the percentage of patients with a complete or partial response out of the patients who had measurable disease at baseline.

Time frame:
Through study treatment, an average of 2 months
Reported as:
Count of participants · Participants
Objective Response Rate (ORR)
ParticipantsLDE225 (Sonidegib) 400mg in Combination With DocetaxelLDE225 (Sonidegib) 600mg in Combination With DocetaxelLDE225 (Sonidegib) 800mg in Combination With Docetaxel
Objective Response Rate (ORR)001

Adverse events

Collected over Through study treatment, average of 2 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LDE225 (Sonidegib) 400mg in Combination With Docetaxel1/5 (20%)0/5 (0%)5/5 (100%)
LDE225 (Sonidegib) 600mg in Combination With Docetaxel0/4 (0%)1/4 (25%)4/4 (100%)
LDE225 (Sonidegib) 800mg in Combination With Docetaxel0/3 (0%)0/3 (0%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventLDE225 (Sonidegib) 400mg in Combination With DocetaxelLDE225 (Sonidegib) 600mg in Combination With DocetaxelLDE225 (Sonidegib) 800mg in Combination With Docetaxel
OverdoseInjury, poisoning and procedural complications0/51/40/3
Most frequent other events
Showing 10 of 46
Most frequent other events
EventLDE225 (Sonidegib) 400mg in Combination With DocetaxelLDE225 (Sonidegib) 600mg in Combination With DocetaxelLDE225 (Sonidegib) 800mg in Combination With Docetaxel
AlopeciaSkin and subcutaneous tissue disorders0/51/43/3
Nail discolorationSkin and subcutaneous tissue disorders0/50/43/3
AnemiaBlood and lymphatic system disorders4/51/41/3
FatigueGeneral disorders2/52/42/3
Mucositis oralGastrointestinal disorders1/51/42/3
ArthralgiaMusculoskeletal and connective tissue disorders2/50/42/3
MyalgiaMusculoskeletal and connective tissue disorders2/50/42/3
Neutrophil count decreasedInvestigations1/50/42/3
NauseaGastrointestinal disorders0/50/42/3
Rash maculo-papularSkin and subcutaneous tissue disorders0/50/42/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)LDE225 (Sonidegib) in Combination With Docetaxel
Mean49.25 ± 13.48
Sex: Female, Male
Sex: Female, Male(Participants)LDE225 (Sonidegib) in Combination With Docetaxel
Female12
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LDE225 (Sonidegib) in Combination With Docetaxel
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White12
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)LDE225 (Sonidegib) in Combination With Docetaxel
Spain12
Menopausal status
Menopausal status(participants)LDE225 (Sonidegib) in Combination With Docetaxel
Pre-menopausal5
Post-menopausal7
08

Study locations

5 sites
  • Complejo Hospitalario Universitario A Coruña
    A Coruña, 15006, Spain
  • Hospital General Universitario Gregorio Marañón
    Madrid, 28007, Spain
  • Hospital Clínico Universitario San Carlos
    Madrid, 28040, Spain
  • Hospital Clínico Universitario Virgen de la Victoria
    Málaga, 29010, Spain
  • Hospital Universitario Virgen del Rocío
    Sevilla, 41071, Spain
09

References and documents

Publications

  • Ruiz-Borrego M, Jimenez B, Antolin S, Garcia-Saenz JA, Corral J, Jerez Y, Trigo J, Urruticoechea A, Colom H, Gonzalo N, Munoz C, Benito S, Caballero R, Bezares S, Carrasco E, Rojo F, Martin M. A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study. Invest New Drugs. 2019 Feb;37(1):98-108. doi: 10.1007/s10637-018-0614-9. Epub 2018 Jun 9. PubMed 29948356 ↗
  • Cazet AS, Hui MN, Elsworth BL, Wu SZ, Roden D, Chan CL, Skhinas JN, Collot R, Yang J, Harvey K, Johan MZ, Cooper C, Nair R, Herrmann D, McFarland A, Deng N, Ruiz-Borrego M, Rojo F, Trigo JM, Bezares S, Caballero R, Lim E, Timpson P, O'Toole S, Watkins DN, Cox TR, Samuel MS, Martin M, Swarbrick A. Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nat Commun. 2018 Jul 24;9(1):2897. doi: 10.1038/s41467-018-05220-6. PubMed 30042390 ↗
10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02027376
Lead sponsor
Spanish Breast Cancer Research Group
Collaborators
Novartis
Responsible party
Sponsor
First posted
Jan 6, 2014
Start date
May 2014
Primary completion
Apr 2016
Completion
Apr 2016
Results posted
Dec 4, 2018
Last update
Apr 3, 2023

Study contacts

Study Director
study director · Hospital General Universitario Gregorio Marañón

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Breast Neoplasms→

Other studies from this sponsor

Spanish Breast Cancer Research Group

Start the discussion